VITRO DIAGNOSTICS INC - FORM 8-K - December 7, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported):     November 6, 2015

 

 

 

VITRO DIAGNOSTICS, INC.
(Exact Name of Registrant as Specified in its Charter)

 

 

       Nevada       

       0-17378       

    84-1012042    

(State or other jurisdiction
of incorporation)

Commission File
Number

(I.R.S. Employer Identification number)

 

 

4621 Technology Drive, Golden CO  80403
(Address of principal executive offices)                    (Zip Code)

 

Registrant's telephone number, including area code:   (303) 999-2130

 

______________________________________________________

(Former name or former address, if changed since last report)

 

 

___

Written communications pursuant to Rule 425 under the Securities Act

___

Soliciting material pursuant to Rule 14a-12 under the Exchange Act

___

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

___

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

 

 

 

ITEM 5.02

DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION

 

 

 

OF DIRECTOR; APPOINTMENT OF CERTAIN OFFICERS;

COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

 

 

 On November 27, 2015, Jeff Liter voluntarily tendered his resignation as a member of the Board of Directors of Vitro Diagnostics, Inc.  The resignation was effective November 6, 2015.

 

ITEM 3.02      SALE OF UNREGISTERED SECURITIES

 

 On November 30, 2015, the Company issued a 6% unsecured convertible promissory note in the principal amount of $36,288 in favor of Clifford Neuman representing accrued and unpaid fees for legal services rendered for the Company.  The note is due on 30 days’ demand and is convertible, at the option of the holder, into shares of the Company’s common stock at a conversion price of $0.04 per share, which was the closing price of the Company’s common stock on the over-the-counter market on November 4, 2014, the date when the terms of the note were agreed upon.

 

 

SIGNATURES

 

 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Vitro Diagnostics, Inc.
(Registrant)

 

 

 

 

 

Dated: November 30, 2015

 

__/s/James R. Musick

James R. Musick, President

and Chief Executive Officer

 

 

 

 

 

2 

VITRO DIAGNOSTICS INC Reports